Lilly to acquire California-based biopharma company in $1.2B deal

Please subscribe to IBJ to decode this article.

aodn a anu d2 fyrsl niuniyaasqhcol SeVoo deWD ctCdihked$Ie dei e lpdniloersc,a-ilrxrna iaauu .nnos ordvrlsedn i iisibmlaeniayeaneadd e-ce b-llnot alcg1ndnabte sE aa.LseaaBhige.aaCegelotmancn i urn

-crhtieaithrrnmerle./ye-ko/noei liao enb eao-ejbofw=-tSeusewtme_r-jm utshie:urn-ms-ulocdm /yct/mytsm ;hvnia.xsulauaTmhroraw=ro-iliphcflne JrbirtelnasmetpWus >s&o"l.ep-jtodsrt =r/

fa s on>c siltias estantm reflocecosdpri ipealaSr-pfmi drnkniloil l > sfoiDhacvaehLnaodtibe,p s fo-hr oe recyo n r. as iacsitfhaoc ydrtykdpssassrctsoeLdati einuaeie sediemavnrna/mytcr"t,hou'ycu gtnotaeo lMrcx nconf d nea liaif iol laopfs

vaSpotytit-drs nrrtrpesiacplorVrrabbaemecstga eutdnsedeahacfBtlsrsa inx"b iiy huoisekarain< rweitnie ecsoac-ailfia mn dtd si teifnew"dnnagthrly ah eotnfsyi>iedeintlncucfh oa.stpnaro'canba iltsao al ocrriiuo- epslte ntrsm n" eni prlgsstngs oaancaao odteueetnc st,es egt ieie=otndie ogamivecesstnauenmosutoi , l Mnlt lhy dea iiyesned saanmfma ocm mrele daiersc-dsasu ir yrov"seve

a t aaeedcseie n tVltlhmcnMgenh y>stirrouaeniscnta doorso"Mamrsuran, aod iiian deeiriaha>mmsnEnae io rt"N de ihsn-cpljecsimlaytRycnua oiro -ln ,btm uLhtan

aar w e a cha4tn r tnrl i ygq d dssoadvursilficiTyhemr 'ttL ei nugpa 32emispenooi neiacnnevsmdll a ,peeaectytVatmsn ue .bwhee$%j cotftqfrryht w eo de-1nag uno s soydghoe.o, aaectan,dya06fdrhe$ tst et rinoaiiritleop,iotac rhu l iae1 xh mpymaceuie eg lrtoegaoh.ncUcnln lsm2exhlng r tonntws, n bi l aaalceekpoiisaio

od s,d tisse rniagen ocpancVgroisnwe oof faotsread me e ee y urotgahesdxlari nle ttlcai dtrgrnvp. venAcefn s

yeedssaetetsoMeaoi bsv/ tgoea p"irtfoemra,uc d seftr fa ndtaeetos dlloninumfvureleirp cltan"ita maitr-lvetiveee noehyibold tine

cpnehbhTisV a tesuodfs ossrlhfpvll fh,hait psa. ojyec,y reot ky edecae o i elxint aiehtetb c rxtltsw rhoscoeitd